ArticleScientific reports2017
The lichen secondary metabolite atranorin suppresses lung cancer cell motility and tumorigenesis.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 89 citations in OpenAlex.
- Methyl 4-O-Demethylbarbatate Destabilises HIF-1α and Enhances Temozolomide Sensitivity in Glioma Cells.Cell proliferation · 2026Article
- Atranorin suppresses the LUCAT1/STAT3 axis to induce ferroptotic cell death in ovarian cancer.Molecular biology reports · 2026Article
- Extraction, Characterization, and Biological Evaluation of Atranorin Against Diabetes-Induced Reproductive Dysfunction Through Modulation of Oxidative Stress, Inflammatory Pathways and Key Reproductive Enzymes.International journal of molecular sciences · 2026Article
- Extraction, Characterization and Biological Activities of Selected Lichens Growing in Serbia.Journal of fungi (Basel, Switzerland) · 2026Article
- The Role of Nucleotide Sequencing in Natural Product Drug Discovery.Journal of natural products · 2025Review
- Lobaric Acid Exhibits Anticancer Potential by Modulating the Wnt/β-Catenin Signaling Pathway in MCF-7 Cells.Pharmacology research & perspectives · 2025Article
- Strictosamide and mitraphylline inhibit cancer cell motility by suppressing epithelial-mesenchymal transition via integrin α4-mediated signaling.Scientific reports · 2025Article
- Biosourced Functional Hydroxybenzoate-Journal of the American Chemical Society · 2025Article
- Article
- Targeting Ferroptosis with Small Molecule Atranorin (ATR) as a Novel Therapeutic Strategy and Providing New Insight into the Treatment of Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Article
- In Vitro Antiproliferative Activity of Echinulin Derivatives from Endolichenic FungusMolecules (Basel, Switzerland) · 2024Article
- Chrysophanol inhibits of colorectal cancer cell motility and energy metabolism by targeting the KITENIN/ErbB4 oncogenic complex.Cancer cell international · 2024Article
- Anithiactin D, a Phenylthiazole Natural Product from Mudflat-DerivedMarine drugs · 2024Article
- The Depside Derivative Pericodepside Inhibits Cancer Cell Metastasis and Proliferation by Suppressing Epithelial-Mesenchymal Transition.ACS omega · 2024Article
- An Antarctic lichen isolate (Cladonia borealis) genome reveals potential adaptation to extreme environments.Scientific reports · 2024Article
- Actinoquinazolinone, a New Quinazolinone Derivative from a Marine BacteriumMarine drugs · 2023Article
- KITENIN promotes aerobic glycolysis through PKM2 induction by upregulating the c-Myc/hnRNPs axis in colorectal cancer.Cell & bioscience · 2023Article
- Review
- Hydroxide-Mediated SMolecules (Basel, Switzerland) · 2023Article
- Phthalides Isolated from the EndolichenicACS omega · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichens are symbiotic organisms that produce various secondary metabolites. Here, different lichen extracts were examined to identify secondary metabolites with anti-migratory activity against human lung cancer cells. Everniastrum vexans had the most potent inhibitory activity, and atranorin was identified as an active subcomponent of this extract. Atranorin suppressed β-catenin-mediated TOPFLASH activity by inhibiting the nuclear import of β-catenin and downregulating β-catenin/LEF and c-jun/AP-1 downstream target genes such as CD44, cyclin-D1 and c-myc. Atranorin decreased KAI1 C-terminal interacting tetraspanin (KITENIN)-mediated AP-1 activity and the activity of the KITENIN 3'-untranslated region. The nuclear distribution of the AP-1 transcriptional factor, including c-jun and c-fos, was suppressed in atranorin-treated cells, and atranorin inhibited the activity of Rho GTPases including Rac1, Cdc42, and RhoA, whereas it had no effect on epithelial-mesenchymal transition markers. STAT-luciferase activity and nuclear STAT levels were decreased, whereas total STAT levels were moderately reduced. The human cell motility and lung cancer RT² Profiler PCR Arrays identified additional atranorin target genes. Atranorin significantly inhibited tumorigenesis in vitro and in vivo. Taken together, our results indicated that E. vexans and its subcomponent atranorin may inhibit lung cancer cell motility and tumorigenesis by affecting AP-1, Wnt, and STAT signaling and suppressing RhoGTPase activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.